Dramatic response to pembrolizumab with chemotherapy followed by salvage surgery in a lung cancer patient

Thoracic Cancer

Seiya Momosaki¹  Koji Yamazaki²  Gouji Toyokawa²  Yuka Kozuma²  Fumihiro Shoji²  Sadanori Takeo²  Shunichi Saito² 

[1] Department of Pathology Clinical Research Institute, National Hospital Organization, Kyushu Medical Center Fukuoka Japan;Department of Thoracic Surgery Clinical Research Institute, National Hospital Organization, Kyushu Medical Center Fukuoka Japan;

关键词: Immunotherapy;    lung cancer;    neoadjuvant therapy;    salvage surgery;   

DOI  :  10.1111/1759-7714.14051

来源: DOAJ

【 摘 要 】

Abstract Immune checkpoint inhibitors with chemotherapy have been shown to exhibit remarkable efficacy for advanced non‐small‐cell lung carcinoma and are under investigation as an induction therapy. However, the significance of preoperative therapy with pembrolizumab + chemotherapy for surgically resectable non‐small‐cell lung carcinoma still remains unclear. Here, we report a case of stage IIIB non‐small‐cell lung carcinoma that underwent salvage surgery after three cycles of pembrolizumab + carboplatin + nab‐paclitaxel. Computed tomography revealed the remarkable decrease in tumor volume by 81%. A pathological examination showed that viable neoplastic cells were observed in <1% of the total tumorous lesion suggesting near pathological complete response. This case suggests that this regimen might be a good option as induction therapy for non‐small‐cell lung carcinoma.

【 授权许可】

Unknown